Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

Jefferies said it still regards GSK’s fundamental value as “compelling,” adding that its 2027+ estimates for sales and ...